Acer Therapeutics Inc., a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
Previous Symbol
CUSIPN/A
Phone844-902-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.26
Quick Ratio3.26
Price-To-Earnings
Trailing P/E Ratio-6.34
Forward P/E Ratio-10.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.90 million
Price / Sales81.65
Cash FlowN/A
Price / CashN/A
Book Value$3.03 per share
Price / Book8.04
Profitability
EPS (Most Recent Fiscal Year)($3.84)
Net Income$-14,190,000.00
Net MarginsN/A
Return on Equity-92.82%
Return on Assets-82.01%
Miscellaneous
Employees6
Outstanding Shares9,720,000
Market Cap$242.10 million
OptionableNot Optionable
Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions
What is Acer Therapeutics' stock symbol?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Acer Therapeutics' earnings last quarter?
Acer Therapeutics Inc (NASDAQ:ACER) released its quarterly earnings results on Monday, November, 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.10. View Acer Therapeutics' Earnings History.
When is Acer Therapeutics' next earnings date?
What price target have analysts set for ACER?
4 analysts have issued 12-month price objectives for Acer Therapeutics' shares. Their forecasts range from $46.00 to $70.00. On average, they expect Acer Therapeutics' share price to reach $57.00 in the next year. This suggests a possible upside of 134.0% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.
What is the consensus analysts' recommendation for Acer Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acer Therapeutics.
Has Acer Therapeutics been receiving favorable news coverage?
Media headlines about ACER stock have been trending positive on Wednesday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acer Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Acer Therapeutics' key competitors?
Some companies that are related to Acer Therapeutics include Uniqure (QURE), Lexicon Pharmaceuticals (LXRX), Alder Biopharmaceuticals (ALDR), Dicerna Pharmaceuticals (DRNA), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Viking Therapeutics (VKTX), Revance Therapeutics (RVNC), Aptinyx (APTX), Akorn (AKRX), Apellis Pharmaceuticals (APLS), Clovis Oncology (CLVS), Athenex (ATNX), Eagle Pharmaceuticals (EGRX) and Cara Therapeutics (CARA).
Who are Acer Therapeutics' key executives?
Acer Therapeutics' management team includes the folowing people:
- Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 42)
- Mr. Harry S. Palmin, COO & CFO (Age 48)
- Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 53)
- Mr. Jefferson Davis, Acting Chief Bus. Officer (Age 51)
- Ms. Kim Tharaldsen, Sr. Director of Marketing
Who are Acer Therapeutics' major shareholders?
Acer Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vivo Capital LLC (5.82%), Heartland Advisors Inc. (2.16%), Emerald Mutual Fund Advisers Trust (1.29%), EAM Investors LLC (0.22%), Monashee Investment Management LLC (0.12%) and Renaissance Technologies LLC (0.12%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm, Steve Aselage and Timothy C Barabe. View Institutional Ownership Trends for Acer Therapeutics.
Which institutional investors are buying Acer Therapeutics stock?
ACER stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Emerald Mutual Fund Advisers Trust, Heartland Advisors Inc., EAM Investors LLC, Monashee Investment Management LLC, Renaissance Technologies LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.
How do I buy shares of Acer Therapeutics?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acer Therapeutics' stock price today?
One share of ACER stock can currently be purchased for approximately $24.36.
How big of a company is Acer Therapeutics?
Acer Therapeutics has a market capitalization of $242.10 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.
What is Acer Therapeutics' official website?
How can I contact Acer Therapeutics?
Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]
MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
